- In May 2024, The U.S. Food and Drug Administration granted the "Breakthrough Device" designation to OrthoPediatrics Corp. for its eLLi Growing Rod System. This implant is designed to address severe pathologies associated with Early Onset Scoliosis (EOS) in pediatric patients, facilitating expedited development and review processes
- In March 2024, OrthoPediatrics Corp. announced the launch of its new RESPONSE Rib and Pelvic Fixation System, designed to treat children with Early Onset Scoliosis (EOS). This system represents the company's 71st solution for pediatric orthopedic conditions, aiming to provide comprehensive treatment options for young patients
- In December 2023, OrthoPediatrics Corp. announced the launch of its Specialty Bracing Division (OPSB), focusing on non-surgical interventions in pediatric orthopedics. This division aims to expand the company's reach in providing comprehensive orthopedic solutions for children
- In October 2023, OrthoPediatrics Corp. joined the Alliance for Pediatric Device Innovation (APDI), led by Children's National Hospital. As a strategic advisor, OrthoPediatrics aims to support the development and commercialization of pediatric medical devices, enhancing innovation in the field
- In July 2022, OrthoPediatrics Corp. completed its acquisition of Pega Medical, a company specializing in innovative technologies for pediatric orthopedic conditions. The acquisition includes Pega's Fassier-Duval Telescopic Intramedullary System, enhancing OrthoPediatrics' portfolio in treating osteogenesis imperfecta and other bone deformities
